Styczeń Krzysztof, Sowa-Kućma Magdalena, Siwek Marcin, Dudek Dominika, Reczyński Witold, Szewczyk Bernadeta, Misztak Paulina, Topór-Mądry Roman, Opoka Włodzimierz, Nowak Gabriel
Department of Affective Disorders, Chair of Psychiatry, Jagiellonian University Medical College, Kopernika 21a, 31-501, Krakow, Poland.
Laboratory of Trace Elements Neurobiology, Institute of Pharmacology PAS, Smetna 12, 31-343, Krakow, Poland.
Metab Brain Dis. 2017 Feb;32(1):97-103. doi: 10.1007/s11011-016-9888-9. Epub 2016 Aug 8.
Despite many clinical trials assessing the role of zinc in major depressive disorder (MDD), the conclusions still remain ambiguous. The aim of the present clinical study was to determine and comparison the zinc concentration in the blood of MDD patients (active stage or remission) and healthy volunteers (controls), as well as to discuss its potential clinical usefulness as a biomarker of the disease. In this study 69 patients with current depressive episode, 45 patients in remission and 50 controls were enrolled. The zinc concentration was measured by electrothermal atomic absorption spectrometry (ET AAS). The obtained results revealed, that the zinc concentration in depressed phase were statistically lower than in the healthy volunteers [0.89 vs. 1.06 mg/L, respectively], while the zinc level in patients achieve remission was not significantly different from the controls [1.07 vs. 1.06 mg/L, respectively]. Additionally, among the patients achieve remission a significant differences in zinc concentration between group with and without presence of drug-resistance in the previous episode of depression were observed. Also, patients in remission demonstrated correlation between zinc level and the average number of depressive episodes in the last year. Serum zinc concentration was not dependent on atypical features of depression, presence of psychotic symptoms or melancholic syndrome, age, age of onset or duration of disease, number of episodes in the life time, duration of the episode/remission and severity of depression measured by the Hamilton Rating Scale for Depression (HDRS), and the Montgomery-Asberg Depression Rating Scale (MADRS). Concluding, our findings confirm the correlation between zinc deficit present in the depressive episode, and are consistent with the majority of previous studies. These results may also indicate that serum zinc concentration might be considered as a potential biological marker of MDD.
尽管有许多临床试验评估锌在重度抑郁症(MDD)中的作用,但结论仍不明确。本临床研究的目的是测定并比较MDD患者(急性期或缓解期)和健康志愿者(对照组)血液中的锌浓度,并讨论其作为该疾病生物标志物的潜在临床实用性。本研究纳入了69例当前有抑郁发作的患者、45例缓解期患者和50例对照组。通过电热原子吸收光谱法(ET AAS)测量锌浓度。获得的结果显示,抑郁期的锌浓度在统计学上低于健康志愿者[分别为0.89 vs. 1.06mg/L],而缓解期患者的锌水平与对照组无显著差异[分别为1.07 vs. 1.06mg/L]。此外,在缓解期患者中,观察到上一次抑郁发作时有和没有耐药性的组之间锌浓度存在显著差异。而且,缓解期患者的锌水平与去年抑郁发作的平均次数之间存在相关性。血清锌浓度不依赖于抑郁症的非典型特征、精神病性症状或 melancholic 综合征的存在、年龄、发病年龄或病程、一生中发作次数、发作/缓解持续时间以及用汉密尔顿抑郁量表(HDRS)和蒙哥马利-阿斯伯格抑郁量表(MADRS)测量的抑郁严重程度。总之,我们的研究结果证实了抑郁发作时存在的锌缺乏之间的相关性,并且与大多数先前的研究一致。这些结果也可能表明血清锌浓度可被视为MDD的潜在生物标志物。